IL27 and neoplasm: The successful application of genome editing in targeting IL30 gene, in both AR+ and AR− human PC cells, and the improved survival of tumor-bearing hosts, provides the proof of concept for the use of CRISPR/Cas9 genome editing of IL30 to counteract prostatic oncogenesis in both the androgen-responsive and unresponsive phases of disease progression.